【摘要】：目的探討液基細(xì)胞學(xué)檢查(TCT)、高危型人乳頭狀瘤病毒DNA(HPV-DNA)及聯(lián)合檢測對宮頸病變篩查的臨床應(yīng)用價值。方法接受宮頸病變篩查的926例患者進(jìn)行TCT、HPV-DNA檢測,異常者予陰道鏡下活檢確診。結(jié)果 926例患者經(jīng)病理檢查826例確診為無內(nèi)皮病變(NILM)者,TCT檢測陽性率為17.07%,25確診為宮頸上皮內(nèi)瘤變(CIN)I,TCT檢測陽性率為72.35%,75例確診為≥CIN II,TCT檢測陽性率為89.33%,HPV-DNA檢測陽性225例。同時HPVDNA特異性、靈敏性、漏診率、誤診率分別為82.93%、65.00%、35.00%、17.07%;TCT特異性、靈敏性、漏診率、誤診率分別為82.08%、66.00%、34.00%、17.92%;二者聯(lián)合特異性、靈敏性、漏診率、誤診率分別為97.58%、98.00%、2.00%、2.42%。結(jié)論臨床應(yīng)用宮頸TCT、HPV-DNA、陰道鏡下活檢進(jìn)行宮頸病變早期篩查是一種有效、可行的篩查方案,可有效提高宮頸病變檢出率,對宮頸癌的早期診斷與治療有著重要的臨床意義。
[Abstract]:Objective to evaluate the clinical value of liquid-based cytologic examination of high-risk human papillomavirus (HPV-DNA) DNA (HPV-DNA) in screening cervical lesions. Methods TCT,HPV-DNA was detected in 926 patients with cervical lesions, and the abnormal cases were diagnosed by colposcopy biopsy. Results the positive rate of (NILM) in 926 patients with no (NILM) was 17.0725. The positive rate of TCT was 72.35%. 75 cases were diagnosed as 鈮，

本文編號：2255992